| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
BILB-1941 targets the hepatitis C virus (HCV) NS5B RNA polymerase, an essential enzyme for viral RNA replication. It is a non-nucleoside inhibitor that binds to the enzyme at an allosteric site, preventing the polymerization of viral RNA. By inhibiting NS5B, BILB-1941 blocks HCV replication. The compound also interferes with viral attachment and fusion, providing additional antiviral activity. Its specificity for HCV polymerase makes it a valuable tool for studying HCV replication and for developing new antiviral therapies.
|
|---|---|
| ln Vitro |
In vitro, BILB-1941 is a potent and specific non-nucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase. It interferes with viral attachment and fusion, providing a tool for mechanistic investigation of early infection stages. The compound is effective in high-throughput evaluation of entry-targeting antiviral compounds. In cell-based assays, BILB-1941 treatment results in reduced HCV RNA replication and viral production. The compound's antiviral activity is assessed using HCV replicon systems or infectious HCV cell culture models.
|
| ln Vivo |
In vivo, BILB-1941 has been studied for its potential in the treatment of HCV infection. As an inhibitor of HCV NS5B polymerase, it blocks viral replication. The compound also interferes with viral attachment and fusion. Comprehensive in vivo efficacy studies are needed to fully characterize its therapeutic potential. BILB-1941 has been studied in preclinical and clinical settings for the treatment of HCV infection.
|
| Enzyme Assay |
In vitro enzyme assays for BILB-1941 involve measuring the inhibition of HCV NS5B RNA polymerase activity. The assay typically uses recombinant NS5B polymerase incubated with varying concentrations of BILB-1941 in the presence of RNA template, nucleotides, and a radiolabeled nucleotide. The incorporation of the radiolabeled nucleotide into RNA is measured, and the IC₅₀ is calculated. These assays confirm the compound's mechanism of action as an NS5B polymerase inhibitor.
|
| Cell Assay |
In vitro cell-based assays for BILB-1941 evaluate its antiviral activity against HCV. HCV replicon cells or infectious HCV cell culture systems are treated with serial dilutions of BILB-1941. Viral RNA replication is measured by RT-PCR or by using reporter genes. Viral production is assessed by measuring HCV core protein or by infectivity assays. Cytotoxicity is assessed in parallel using uninfected cells. These assays confirm the compound's antiviral activity.
|
| Animal Protocol |
In vivo animal experiments for BILB-1941 have been conducted in animal models of HCV infection, such as humanized mouse models or other surrogate models. The compound is administered orally or via injection, and viral load is monitored over time. Pharmacokinetic studies are conducted to determine the compound's half-life, clearance, and tissue distribution. Comprehensive in vivo studies are needed to fully characterize its efficacy and safety.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for BILB-1941 are available from preclinical and clinical studies. The compound has a molecular weight of 562.66 g/mol and is typically administered orally. Its half-life, bioavailability, and excretion profile have been characterized in the context of its development for HCV treatment. The compound's metabolic stability and potential for drug-drug interactions have been studied. Comprehensive PK data are available from pharmaceutical studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BILB-1941 has been evaluated in preclinical and clinical studies. As an antiviral agent, the compound is generally well-tolerated at therapeutic doses. Common side effects may include gastrointestinal disturbances and headache. The compound should be used under medical supervision. Comprehensive toxicological studies are available from clinical development. BILB-1941 is for research use only and is not for human use without proper authorization.
|
| References | |
| Additional Infomation |
BILB-1941 is a potent and specific non-nucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase (NS5B) in vitro. It has a molecular formula of C₃₄H₃₄N₄O₄ and a molecular weight of 562.66 g/mol. BILB-1941 interferes with viral attachment and fusion. It is effective in high-throughput evaluation of entry-targeting antiviral compounds. The compound can be used in studies about HCV infection.
|
| CAS # |
494856-61-0
|
|---|---|
| PubChem CID |
56949326
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
42
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
